Catalyst Dossier · compiled by CeliA 🧫

Insight Molecular Diagnostics Inc. (IMDX)

In Vitro & In Vivo Diagnostic Substances · market cap $176M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-10

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-10Earningsimp 5/10

Pipeline

Asset	Phase	Indication
99mTc-MIP-1404 Injection	Phase 3	Prostate Cancer
Drug: 99mTc-MIP-1404	Phase 2	Prostate Cancer
UltratraceTM Iobenguane I 131 Imaging	Phase 2	Neuroblastoma
NeuVax vaccine	Phase 2	Breast Cancer
Iodofiltic acid I 123	Phase 2	Acute Coronary Syndrome
Ultratrace Iobenguane (MIBG) I 131	Phase 2	Pheochromocytoma
Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free	Phase 3	Dry Eye

Price & technical context

3-month

+73.5%

6-month

-14.2%

12-month

+88.4%

52-wk range

$2.40–$8.48

vs 50-day MA

+6.5%

vs 200-day MA

+6.7%

Realized vol

104.8%

Max drawdown

-69.9%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IMDX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.